Core Viewpoint - Chuangli Medical (01858) has seen a stock price increase of over 3%, currently trading at 17.62 HKD with a transaction volume of 28.2853 million HKD, following the announcement of a strategic investment in a healthcare-focused fund [1] Group 1: Investment Details - The company announced a joint investment with Nanchang Defu Investment Consulting Partnership (Limited Partnership) and other partners in the Nanchang Defu Phase IV Equity Investment Fund Partnership (Limited Partnership) [1] - The fund primarily targets growth and mature stage enterprises/projects in the healthcare industry, aligning with the company's core business [1] - The company, as a limited partner, has invested 50 million RMB, representing 9.2105% of the fund's total shares [1] Group 2: Strategic Implications - This investment aligns with the company's strategic development direction and is expected to enhance its industrial layout [1] - The collaboration is anticipated to leverage the investment experience and resource advantages of the partners, promoting deep integration of industrial operations and capital management [1] - The goal is to create a virtuous cycle of collaborative development, thereby improving the company's core competitiveness and overall profitability, leading to sustainable, safe, healthy, and stable high-quality growth [1]

Core Viewpoint - Spring Medical (688236.SH) has signed a partnership agreement with Nanchang Defu Investment Consulting Partnership and other partners to invest in the healthcare industry [1] Group 1: Investment Details - The total subscribed capital of the partnership is 542.857143 million yuan, with the company contributing 50 million yuan, accounting for 9.2105% of the total subscribed capital [1] - The investment targets of the partnership focus on enterprises/projects in the healthcare industry that are in the growth or mature stages [1]